SI2877206T1 - Sestavki, ki obsegajo himerne OSPA molekule in metode njihove uporabe - Google Patents

Sestavki, ki obsegajo himerne OSPA molekule in metode njihove uporabe

Info

Publication number
SI2877206T1
SI2877206T1 SI201331676T SI201331676T SI2877206T1 SI 2877206 T1 SI2877206 T1 SI 2877206T1 SI 201331676 T SI201331676 T SI 201331676T SI 201331676 T SI201331676 T SI 201331676T SI 2877206 T1 SI2877206 T1 SI 2877206T1
Authority
SI
Slovenia
Prior art keywords
compositions
methods
chimeric ospa
ospa molecules
molecules
Prior art date
Application number
SI201331676T
Other languages
English (en)
Slovenian (sl)
Inventor
Noel P. Barrett
Gerald Aichinger
Brian A. Crowe
Ian Livey
Nina Wressnigg
Original Assignee
Baxalta GmbH
Baxalta Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta GmbH, Baxalta Incorporated filed Critical Baxalta GmbH
Publication of SI2877206T1 publication Critical patent/SI2877206T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1207—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SI201331676T 2012-07-27 2013-07-11 Sestavki, ki obsegajo himerne OSPA molekule in metode njihove uporabe SI2877206T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261676668P 2012-07-27 2012-07-27
PCT/US2013/050058 WO2014018274A1 (en) 2012-07-27 2013-07-11 Compositions comprising chimeric ospa molecules and methods of use thereof
EP13742553.4A EP2877206B1 (en) 2012-07-27 2013-07-11 Compositions comprising chimeric ospa molecules and methods of use thereof

Publications (1)

Publication Number Publication Date
SI2877206T1 true SI2877206T1 (sl) 2020-07-31

Family

ID=48901170

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201331676T SI2877206T1 (sl) 2012-07-27 2013-07-11 Sestavki, ki obsegajo himerne OSPA molekule in metode njihove uporabe

Country Status (11)

Country Link
US (1) US9023367B2 (OSRAM)
EP (2) EP3682897A1 (OSRAM)
JP (1) JP2015524802A (OSRAM)
KR (2) KR20200068756A (OSRAM)
CN (1) CN104640563A (OSRAM)
AU (3) AU2013293448A1 (OSRAM)
CA (1) CA2879689A1 (OSRAM)
PL (1) PL2877206T3 (OSRAM)
RU (1) RU2015106742A (OSRAM)
SI (1) SI2877206T1 (OSRAM)
WO (1) WO2014018274A1 (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2569008T1 (sl) * 2010-05-14 2020-02-28 Baxalta Incorporated Himere OSPA in njihova uporaba v cepivih
JP6405103B2 (ja) * 2014-03-18 2018-10-17 日本製粉株式会社 ソバアレルゲン特異的モノクローナル抗体
CZ2014320A3 (cs) * 2014-05-09 2015-11-18 VÝZKUMNÝ ÚSTAV VETERINÁRNÍHO LÉKAŘSTVÍ, v.v.i. Polyepitopový antigen, vakcinační konstrukt a vakcína pro prevenci lymeské boreliózy
CN106771250B (zh) * 2017-01-06 2018-08-21 杭州京北生物科技有限公司 一种用于检测哺乳动物莱姆病的荧光素酶免疫共沉淀试剂盒
CN115698044A (zh) * 2020-04-09 2023-02-03 瓦尔尼瓦奥地利有限责任公司 用于医学用途的包含三种OspA融合蛋白的组合物
CA3244889A1 (en) 2022-03-08 2023-09-14 Equashield Medical Ltd FLUID TRANSFER STATION IN A ROBOTIC PHARMACEUTICAL PREPARATION SYSTEM
WO2025015042A1 (en) 2023-07-10 2025-01-16 Dynavax Technologies Corporation Lyme disease vaccines comprising an adjuvant and a borrelia outer surface protein a antigen
WO2025015077A1 (en) 2023-07-10 2025-01-16 Dynavax Technologies Corporation Lyme disease vaccines comprising an adjuvant and borrelia outer surface protein a and c antigens

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US4877612A (en) 1985-05-20 1989-10-31 Frank M. Berger Immunological adjuvant and process for preparing the same, pharmaceutical compositions, and process
DE3521994A1 (de) 1985-06-20 1987-01-02 Bayer Ag N-(2-aminoacylamido-2-desoxy-hexosyl)-amide-, -carbamate und -harnstoffe, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
DK166762B1 (da) 1986-01-14 1993-07-12 Nederlanden Staat Fremgangsmaade til fremstilling af immunogenkomplekser og farmaceutisk sammensaetning indeholdende saadanne komplekser
US4806352A (en) 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
US5777095A (en) 1988-10-24 1998-07-07 Symbicom Aktiebolag Osp A and B Sequence of Borrelia burgdonferi strains ACA1 and IP90
US6143872A (en) 1988-10-24 2000-11-07 Symbicom Aktiebolag Borrelia burdorferi Osp A and B proteins and immunogenic peptides
US7094391B1 (en) 1988-10-24 2006-08-22 The University Of Texas System Compositions and methods for administering Borrelia burgdorferi antigens
CA2006596C (en) 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
EP0571538B1 (en) 1991-02-15 1998-07-08 The Uab Research Foundation Structural gene of pneumococcal protein
US6676942B1 (en) 1991-08-15 2004-01-13 Smithkline Beecham Biologicals (S.A.) Osp a proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
EP0877085A1 (en) 1991-08-15 1998-11-11 SMITHKLINE BEECHAM BIOLOGICALS s.a. OspA protein of borrelia burgdorferi subgroups, encoding genes and vaccines
US5234784A (en) 1992-04-01 1993-08-10 Eastman Kodak Company Method of making a projection viewable transparency comprising an electrostatographic toner image
US6248562B1 (en) 1993-11-01 2001-06-19 Research Foundation State University Of New York Chimeric proteins comprising borrelia polypeptides and uses therefor
US7008625B2 (en) 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
CA2175567C (en) 1993-11-01 2010-08-10 John J. Dunn Chimeric proteins comprising borrelia polypeptides: uses therefor
DK0880360T3 (da) 1996-02-12 2003-01-27 Ml Lab Plc Hidtil ukendte fremgangsmåder til vaccination og vacciner dertil, hvilke vacciner omfatter en nucleinsyre, der koder en første epitop, og et peptid, der indeholder en sekundær epitop
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
GB9726555D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Vaccine
GB9811219D0 (en) 1998-05-26 1998-07-22 Smithkline Beecham Biolog Novel process
AU4800500A (en) * 1999-06-21 2001-01-09 Milkhaus Laboratory, Inc. Method for treatment of lyme disease
US6689364B2 (en) 2000-03-21 2004-02-10 Tufts University Borrelia burgdorferi polypeptides and uses thereof
DK1311540T3 (da) 2000-08-18 2008-04-28 Brookhaven Sciences Ass Llc Ændret OspA af Borrelia Burgdorferi
EP1939294A1 (en) 2000-08-18 2008-07-02 Research Foundation Of State University Of New York Recombinant constructs of borrelia burgdorferi
AU2001281145A1 (en) 2000-08-18 2002-03-04 Brookhaven Sciences Associates, Llc Recombinant constructs of borrelia burgdorferi
EP1768688A4 (en) 2004-07-02 2009-09-30 Raymond J Dattwyler ORAL BORRELIOSE VACCINE
AU2008217189B2 (en) 2007-02-22 2013-06-13 Baxalta GmbH Method of purification of hydrophobic proteins
WO2009131665A1 (en) 2008-04-22 2009-10-29 Research Foundation Of State University Of New York Borrelia burgdorferi cell envelope protein array
US20110262475A1 (en) 2008-05-02 2011-10-27 Earnhart Christopher G Lyme disease vaccine
SI2569008T1 (sl) 2010-05-14 2020-02-28 Baxalta Incorporated Himere OSPA in njihova uporaba v cepivih

Also Published As

Publication number Publication date
US9023367B2 (en) 2015-05-05
AU2018203336B2 (en) 2019-10-31
JP2015524802A (ja) 2015-08-27
KR20200068756A (ko) 2020-06-15
EP2877206B1 (en) 2019-11-27
RU2015106742A (ru) 2016-09-20
HK1208627A1 (en) 2016-03-11
AU2020200708A1 (en) 2020-02-20
KR20150038380A (ko) 2015-04-08
CN104640563A (zh) 2015-05-20
AU2013293448A1 (en) 2015-02-05
WO2014018274A1 (en) 2014-01-30
WO2014018274A8 (en) 2015-03-12
CA2879689A1 (en) 2014-01-30
PL2877206T3 (pl) 2020-12-14
EP2877206A1 (en) 2015-06-03
US20140030284A1 (en) 2014-01-30
EP3682897A1 (en) 2020-07-22
AU2018203336A1 (en) 2018-05-31

Similar Documents

Publication Publication Date Title
EP2834322A4 (en) BIOCHARBON COMPOSITIONS AND METHODS OF USE
IL234108B (en) Preparations of factor viii and methods for their preparation and use
SG10201609940RA (en) Compounds and their methods of use
EP2675471A4 (en) HSA-RELATED COMPOSITIONS AND USE PROCESSES
AP3965A (en) Anthelminitic compounds and compositions and method of using thereof
SG11201501499SA (en) Multi-functional compositions and methods of use
ZA201408594B (en) Xylitol-based anti-mucosal compositions and related methods and compositions
SG10201913382YA (en) Topical compositions and methods of use
EP2953605A4 (en) USE OF A COSMETIC COMPOSITION
ZA201406082B (en) Use of ccr3-inhibitors
PL2877206T3 (pl) Kompozycje zawierające chimeryczne cząsteczki ospa i sposoby ich zastosowania
IL235968A0 (en) Polysaccharide preparations and methods of use
EP2668044A4 (en) COMPOSITIONS AND THEIR USE
EP2852370A4 (en) FLASH-CONTAINING COMPOSITIONS AND METHODS OF USE
IL233961B (en) The composition of a phytogenic supplement and methods of its use
EP2859071A4 (en) CHEMICAL COMPOSITIONS AND METHODS OF USE
ZA201408128B (en) Etract of greyia radlkoferi and use thereof
SG10201500715XA (en) Composition for Multiple Health Benefits and Methods Thereof
AU2012901658A0 (en) Compositions and methods of use
GB201215414D0 (en) Composition and use